XTL Biopharmaceuticals Ltd. (XTLB)
USD 1.13
(-3.02%)
USD 1.13
(-3.02%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 765 Thousand USD | -99.8% |
| 2022 | 880 Thousand USD | -14.65% |
| 2021 | 1.03 Million USD | 8.76% |
| 2020 | 948 Thousand USD | 12.59% |
| 2019 | 842 Thousand USD | 6.18% |
| 2018 | 793 Thousand USD | -36.36% |
| 2017 | 1.24 Million USD | -27.26% |
| 2016 | 1.71 Million USD | -14.22% |
| 2015 | 1.99 Million USD | -1.24% |
| 2014 | 2.02 Million USD | -47.51% |
| 2013 | 3.85 Million USD | 4.05% |
| 2012 | 3.7 Million USD | 219.97% |
| 2011 | 1.15 Million USD | -7.88% |
| 2010 | 1.25 Million USD | -45.15% |
| 2009 | 2.29 Million USD | -85.26% |
| 2008 | 15.53 Million USD | -41.46% |
| 2007 | 26.53 Million USD | 61.33% |
| 2006 | 16.44 Million USD | 26.54% |
| 2005 | 12.99 Million USD | -23.23% |
| 2004 | 16.92 Million USD | 216.25% |
| 2003 | -14.56 Million USD | -182.22% |
| 2002 | 17.71 Million USD | 17.11% |
| 2001 | 15.12 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 175 Thousand USD | 52452.55% |
| 2023 FY | 1746.00 USD | -99.8% |
| 2023 Q4 | 200 Thousand USD | 32.45% |
| 2023 Q1 | 251 Thousand USD | 11.56% |
| 2023 Q2 | 163 Thousand USD | -35.06% |
| 2023 Q3 | 151 Thousand USD | -7.36% |
| 2022 Q2 | 202 Thousand USD | -18.88% |
| 2022 Q4 | 225 Thousand USD | 10.29% |
| 2022 Q3 | 204 Thousand USD | 0.99% |
| 2022 FY | 880 Thousand USD | -14.65% |
| 2022 Q1 | 249 Thousand USD | -12.94% |
| 2021 Q2 | 535 Thousand USD | 130.6% |
| 2021 Q3 | 442 Thousand USD | -17.38% |
| 2021 Q4 | 286 Thousand USD | -35.29% |
| 2021 FY | 1.03 Million USD | 8.76% |
| 2021 Q1 | 232 Thousand USD | -9.73% |
| 2020 Q1 | 257 Thousand USD | 5.33% |
| 2020 FY | 948 Thousand USD | 12.59% |
| 2020 Q2 | 474 Thousand USD | 84.44% |
| 2020 Q4 | 257 Thousand USD | 18.43% |
| 2020 Q3 | 217 Thousand USD | -54.22% |
| 2019 Q4 | 244 Thousand USD | 22.61% |
| 2019 Q2 | 200 Thousand USD | 0.5% |
| 2019 Q1 | 199 Thousand USD | -9.95% |
| 2019 Q3 | 199 Thousand USD | -0.5% |
| 2019 FY | 842 Thousand USD | 6.18% |
| 2018 Q2 | 184 Thousand USD | -7.07% |
| 2018 FY | 793 Thousand USD | -36.36% |
| 2018 Q4 | 221 Thousand USD | 16.32% |
| 2018 Q3 | 190 Thousand USD | 3.26% |
| 2018 Q1 | 198 Thousand USD | -30.77% |
| 2017 Q2 | 443 Thousand USD | 35.47% |
| 2017 Q3 | 190 Thousand USD | -57.11% |
| 2017 FY | 1.24 Million USD | -27.26% |
| 2017 Q4 | 286 Thousand USD | 50.53% |
| 2017 Q1 | 327 Thousand USD | -5.22% |
| 2016 FY | 1.71 Million USD | -14.22% |
| 2016 Q1 | 602 Thousand USD | -19.09% |
| 2016 Q4 | 345 Thousand USD | 15.0% |
| 2016 Q3 | 300 Thousand USD | -35.62% |
| 2016 Q2 | 466 Thousand USD | -22.59% |
| 2015 Q2 | 481 Thousand USD | 27.93% |
| 2015 Q3 | 396 Thousand USD | -17.67% |
| 2015 Q1 | 376 Thousand USD | 156.12% |
| 2015 FY | 1.99 Million USD | -1.24% |
| 2015 Q4 | 744 Thousand USD | 87.88% |
| 2014 Q4 | -670 Thousand USD | -201.52% |
| 2014 Q1 | 1.18 Million USD | -29.03% |
| 2014 Q2 | 849 Thousand USD | -28.23% |
| 2014 FY | 2.02 Million USD | -47.51% |
| 2014 Q3 | 660 Thousand USD | -22.26% |
| 2013 Q2 | 1.32 Million USD | -5.23% |
| 2013 Q1 | 1.39 Million USD | 19.81% |
| 2013 FY | 3.85 Million USD | 4.05% |
| 2013 Q4 | 1.66 Million USD | 411.01% |
| 2013 Q3 | -536 Thousand USD | -140.48% |
| 2012 Q3 | 769 Thousand USD | 28.81% |
| 2012 Q4 | 1.16 Million USD | 51.63% |
| 2012 Q1 | 401 Thousand USD | 30.62% |
| 2012 FY | 3.7 Million USD | 219.97% |
| 2012 Q2 | 597 Thousand USD | 48.88% |
| 2011 Q4 | 307 Thousand USD | -1.29% |
| 2011 FY | 1.15 Million USD | -7.88% |
| 2011 Q3 | 311 Thousand USD | 5.07% |
| 2011 Q2 | 296 Thousand USD | -11.38% |
| 2011 Q1 | 334 Thousand USD | 8.44% |
| 2010 Q3 | 296 Thousand USD | -6.62% |
| 2010 Q2 | 317 Thousand USD | -5.37% |
| 2010 FY | 1.25 Million USD | -45.15% |
| 2010 Q1 | 335 Thousand USD | 9.84% |
| 2010 Q4 | 308 Thousand USD | 4.05% |
| 2009 Q2 | 1.21 Million USD | -26.31% |
| 2009 FY | 2.29 Million USD | -85.26% |
| 2009 Q3 | -14 Thousand USD | -101.15% |
| 2009 Q1 | 1.64 Million USD | 98.79% |
| 2009 Q4 | 305 Thousand USD | 2278.57% |
| 2008 Q1 | - USD | -100.0% |
| 2008 Q3 | 3.35 Million USD | -40.02% |
| 2008 FY | 15.53 Million USD | -41.46% |
| 2008 Q4 | 828 Thousand USD | -75.35% |
| 2008 Q2 | 5.6 Million USD | 0.0% |
| 2007 Q4 | 16.87 Million USD | 0.0% |
| 2007 Q1 | - USD | -100.0% |
| 2007 Q2 | 7.7 Million USD | 0.0% |
| 2007 FY | 26.53 Million USD | 61.33% |
| 2007 Q3 | - USD | -100.0% |
| 2006 Q3 | - USD | -100.0% |
| 2006 Q1 | - USD | -100.0% |
| 2006 Q4 | 11.95 Million USD | 0.0% |
| 2006 FY | 16.44 Million USD | 26.54% |
| 2006 Q2 | 3.85 Million USD | 0.0% |
| 2005 Q2 | 2.64 Million USD | 0.0% |
| 2005 Q1 | - USD | 100.0% |
| 2005 Q4 | 10.13 Million USD | 0.0% |
| 2005 FY | 12.99 Million USD | -23.23% |
| 2005 Q3 | - USD | -100.0% |
| 2004 Q2 | 5.06 Million USD | 0.0% |
| 2004 Q4 | -20.23 Million USD | 0.0% |
| 2004 Q3 | - USD | -100.0% |
| 2004 FY | 16.92 Million USD | 216.25% |
| 2004 Q1 | - USD | 0.0% |
| 2003 FY | -14.56 Million USD | -182.22% |
| 2002 FY | 17.71 Million USD | 17.11% |
| 2001 FY | 15.12 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Caribou Biosciences, Inc. | 150.53 Million USD | 99.492% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | 88.636% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | 97.404% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 98.491% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | 99.544% |
| C4 Therapeutics, Inc. | 159.78 Million USD | 99.521% |
| Agenus Inc. | 78.18 Million USD | 99.022% |
| Fortress Biotech, Inc. | 200.19 Million USD | 99.618% |
| GlycoMimetics, Inc. | 39.28 Million USD | 98.053% |
| Novavax, Inc. | 779.12 Million USD | 99.902% |
| Keros Therapeutics, Inc. | 169.27 Million USD | 99.548% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | 96.562% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | 99.209% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | 99.421% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 99.62% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 99.958% |
| AlloVir, Inc. | 180.93 Million USD | 99.577% |
| Aptorum Group Limited | 10.56 Thousand USD | -7140.204% |
| Ardelyx, Inc. | 169.93 Million USD | 99.55% |
| Bicycle Therapeutics plc | 216.92 Million USD | 99.647% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | 99.555% |
| Chimerix, Inc. | 93.38 Million USD | 99.181% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | 94.5% |
| CRISPR Therapeutics AG | 463.49 Million USD | 99.835% |
| Clearside Biomedical, Inc. | 32.71 Million USD | 97.662% |
| Precision BioSciences, Inc. | 92.46 Million USD | 99.173% |
| Dyadic International, Inc. | 9.15 Million USD | 91.642% |
| Elevation Oncology, Inc. | 45.44 Million USD | 98.317% |
| Fortress Biotech, Inc. | 200.19 Million USD | 99.618% |
| GT Biopharma, Inc. | 13.57 Million USD | 94.365% |
| Alkermes plc | 996.24 Million USD | 99.923% |
| Immix Biopharma, Inc. | 16.14 Million USD | 95.261% |
| Innoviva, Inc. | 132.15 Million USD | 99.421% |
| IO Biotech, Inc. | 91.44 Million USD | 99.163% |
| Jaguar Health, Inc. | 42.01 Million USD | 98.179% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | 99.093% |
| ContextLogic Inc. | 387 Million USD | 99.802% |
| AbCellera Biologics Inc. | 275.23 Million USD | 99.722% |
| Lantern Pharma Inc. | 17.87 Million USD | 95.721% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | 90.948% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 99.828% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 99.799% |
| MEI Pharma, Inc. | 34.78 Million USD | 97.801% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | 99.097% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | 96.853% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | 99.523% |
| NextCure, Inc. | 67.63 Million USD | 98.869% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | 97.664% |
| ChromaDex Corporation | 56.37 Million USD | 98.643% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | 99.515% |
| Incyte Corporation | 1.19 Billion USD | 99.936% |
| Opthea Limited | 191.96 Million USD | 99.601% |
| MiMedx Group, Inc. | 229.72 Million USD | 99.667% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | 98.56% |
| Aadi Bioscience, Inc. | 93.47 Million USD | 99.182% |
| Psyence Biomedical Ltd. | 2.75 Million USD | 72.198% |
| Vaxcyte, Inc. | 468.04 Million USD | 99.837% |
| PDS Biotechnology Corporation | 43.04 Million USD | 98.223% |
| Pharming Group N.V. | 225.49 Million USD | 99.661% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | 98.946% |
| Onconetix, Inc. | 34.9 Million USD | 97.808% |
| Acelyrin, Inc. | 422.06 Million USD | 99.819% |
| PureTech Health plc | 144.59 Million USD | 99.471% |
| Pyxis Oncology, Inc. | 82.19 Million USD | 99.069% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 99.688% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | 96.06% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | 96.853% |
| ESSA Pharma Inc. | 32.13 Million USD | 97.619% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | 99.413% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | 97.416% |
| Seer, Inc. | 110.49 Million USD | 99.308% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 99.665% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | 97.98% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | 97.521% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -5832.992% |
| Summit Therapeutics Inc. | 87.68 Million USD | 99.128% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | 97.936% |
| Senti Biosciences, Inc. | 94.7 Million USD | 99.192% |
| ImmuCell Corporation | 9.61 Million USD | 92.046% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | 97.514% |
| Janux Therapeutics, Inc. | 81.06 Million USD | 99.056% |
| Precigen, Inc. | 84.18 Million USD | 99.091% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | 98.652% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | 93.998% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | 99.381% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 99.546% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | 80.594% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 99.81% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | 98.916% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | 97.756% |
| VYNE Therapeutics Inc. | 29.68 Million USD | 97.423% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 95.618% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 99.578% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 99.699% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | 95.959% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 99.652% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 99.705% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | 98.585% |
| Alzamend Neuro, Inc. | 9.93 Million USD | 92.302% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 99.705% |
| Aptose Biosciences Inc. | 52.35 Million USD | 98.539% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | 94.691% |
| Soligenix, Inc. | 7.79 Million USD | 90.186% |
| Century Therapeutics, Inc. | 56.07 Million USD | 98.636% |
| Kura Oncology, Inc. | 165.8 Million USD | 99.539% |
| TScan Therapeutics, Inc. | 114.5 Million USD | 99.332% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | 90.804% |
| Ocean Biomedical, Inc. | 2.48 Million USD | 69.174% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | 99.29% |
| Autolus Therapeutics plc | 196.72 Million USD | 99.611% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | 99.096% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | 99.343% |
| Eterna Therapeutics Inc. | 19.38 Million USD | 96.053% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 99.762% |
| GRI Bio, Inc. | 11.33 Million USD | 93.248% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | 89.158% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | 99.417% |
| IGM Biosciences, Inc. | 265.59 Million USD | 99.712% |
| INmune Bio, Inc. | 29.89 Million USD | 97.441% |
| Heron Therapeutics, Inc. | 172.55 Million USD | 99.557% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 98.102% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | 95.213% |
| Entero Therapeutics, Inc. | 15.74 Million USD | 95.14% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | 98.768% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | 99.289% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 99.723% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 99.746% |
| Verastem, Inc. | 92.08 Million USD | 99.169% |
| Abeona Therapeutics Inc. | 17.93 Million USD | 95.736% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 99.588% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | 99.37% |
| Histogen Inc. | 14.27 Million USD | 94.64% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | 95.233% |
| Surrozen, Inc. | 18.55 Million USD | 95.876% |
| Organovo Holdings, Inc. | 14.91 Million USD | 94.871% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | 84.971% |
| Ovid Therapeutics Inc. | 59.67 Million USD | 98.718% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 97.017% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | 98.373% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | 89.978% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 99.571% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | 98.421% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 99.688% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | 95.022% |
| Apollomics, Inc. | 54.14 Million USD | 98.587% |
| Amarin Corporation plc | 272.35 Million USD | 99.719% |
| Mesoblast Limited | 5.9 Million USD | 87.038% |
| Turnstone Biologics Corp. | 78.33 Million USD | 99.023% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 99.687% |
| Synaptogenix, Inc. | 8.31 Million USD | 90.798% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | 94.755% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 99.698% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | 97.705% |
| Monopar Therapeutics Inc. | 8.83 Million USD | 91.338% |
| Exelixis, Inc. | 1.58 Billion USD | 99.952% |
| Better Therapeutics, Inc. | 38.26 Million USD | 98.001% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 99.67% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 99.911% |
| NLS Pharmaceutics AG | 11.8 Million USD | 93.521% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | 90.487% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 97.449% |
| Gritstone bio, Inc. | 148.37 Million USD | 99.484% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 98.889% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | 95.324% |
| Avid Bioservices, Inc. | 25.99 Million USD | 97.057% |
| Insmed Incorporated | 949.26 Million USD | 99.919% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | 95.124% |
| MediWound Ltd. | 18.86 Million USD | 95.946% |
| OmniAb, Inc. | 83.89 Million USD | 99.088% |
| Alector, Inc. | 248.8 Million USD | 99.693% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 99.674% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | 98.536% |
| Zai Lab Limited | 547.47 Million USD | 99.86% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 99.808% |
| Aura Biosciences, Inc. | 84.99 Million USD | 99.1% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 99.69% |
| Immunic, Inc. | 99.22 Million USD | 99.229% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | 99.519% |
| Veracyte, Inc. | 357.93 Million USD | 99.786% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 99.992% |
| FibroGen, Inc. | 398.11 Million USD | 99.808% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | 94.616% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | 88.894% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | 89.264% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 99.977% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | 97.043% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 99.758% |
| TG Therapeutics, Inc. | 198.47 Million USD | 99.615% |
| Galecto, Inc. | 35.62 Million USD | 97.853% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 98.12% |
| Fortrea Holdings Inc. | 457.3 Million USD | 99.833% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | 98.591% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | 97.351% |
| XBiotech Inc. | 37.51 Million USD | 97.961% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 98.889% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | 96.295% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | 99.461% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | 99.228% |
| Theravance Biopharma, Inc. | 110.71 Million USD | 99.309% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 99.92% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | 97.348% |
| Vaxxinity, Inc. | 56.05 Million USD | 98.635% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 99.822% |
| Gain Therapeutics, Inc. | 22.3 Million USD | 96.571% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | 99.31% |
| NexImmune, Inc. | 28.16 Million USD | 97.284% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | 86.169% |
| Marker Therapeutics, Inc. | 17.89 Million USD | 95.724% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 99.973% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | 96.995% |
| Scopus BioPharma Inc. | 11.71 Million USD | 93.47% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | 99.398% |
| Ainos, Inc. | 12.95 Million USD | 94.094% |
| Pluri Inc. | 22.48 Million USD | 96.597% |
| Prothena Corporation plc | 282.4 Million USD | 99.729% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 99.618% |
| Celularity Inc. | 215.05 Million USD | 99.644% |
| Rallybio Corporation | 78.93 Million USD | 99.031% |
| Cue Biopharma, Inc. | 19.54 Million USD | 96.085% |
| MeiraGTx Holdings plc | 151.07 Million USD | 99.494% |
| Omeros Corporation | 94.75 Million USD | 99.193% |
| Humacyte, Inc. | 23.49 Million USD | 96.744% |
| Immunocore Holdings plc | 308.04 Million USD | 99.752% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | 77.434% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | 99.119% |
| Blueprint Medicines Corporation | 722.86 Million USD | 99.894% |
| CalciMedica, Inc. | 21.81 Million USD | 96.494% |
| Cabaletta Bio, Inc. | 74.66 Million USD | 98.975% |
| Scholar Rock Holding Corporation | 171.29 Million USD | 99.553% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 99.741% |
| Pulmatrix, Inc. | 22.03 Million USD | 96.529% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | 97.787% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | 99.139% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 99.861% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | 98.946% |
| Cytokinetics, Incorporated | 173.61 Million USD | 99.559% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 97.777% |
| Nutriband Inc. | 5.73 Million USD | 86.659% |
| Protara Therapeutics, Inc. | 43.61 Million USD | 98.246% |
| Vor Biopharma Inc. | 126.03 Million USD | 99.393% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 99.936% |
| Evogene Ltd. | 27.79 Million USD | 97.247% |
| ProKidney Corp. | 151.52 Million USD | 99.495% |
| Applied Therapeutics, Inc. | 74.17 Million USD | 98.969% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | 90.055% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 99.875% |
| CorMedix Inc. | 48.95 Million USD | 98.437% |
| BioLineRx Ltd. | 50.8 Million USD | 98.494% |
| Tango Therapeutics, Inc. | 150.7 Million USD | 99.492% |
| Galectin Therapeutics Inc. | 38.07 Million USD | 97.991% |
| Atai Life Sciences N.V. | 125.78 Million USD | 99.392% |
| Renovaro Biosciences Inc. | 81.63 Million USD | 99.063% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | 99.06% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 99.697% |
| Sagimet Biosciences Inc. | 32.74 Million USD | 97.663% |
| MediciNova, Inc. | 10.9 Million USD | 92.982% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | 99.406% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | 89.462% |
| GeoVax Labs, Inc. | 6.02 Million USD | 87.297% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 99.839% |
| Biomea Fusion, Inc. | 126.13 Million USD | 99.394% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 99.942% |
| Mereo BioPharma Group plc | 35.84 Million USD | 97.866% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 99.6% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 99.667% |
| Absci Corporation | 73.66 Million USD | 98.962% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 97.226% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | 99.427% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 99.684% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 99.708% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 99.632% |
| Allakos Inc. | 196.05 Million USD | 99.61% |
| Imunon, Inc. | 20.31 Million USD | 96.233% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | 99.326% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 99.792% |
| BioAtla, Inc. | 129.68 Million USD | 99.41% |
| NLS Pharmaceutics AG | 11.8 Million USD | 93.521% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | 95.171% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | 99.099% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | 98.168% |
| XOMA Corporation | 46.46 Million USD | 98.354% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | 99.312% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 99.463% |
| aTyr Pharma, Inc. | 12.97 Million USD | 94.106% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | 99.262% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 99.557% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 99.7% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | 97.955% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | 90.699% |
| Akari Therapeutics, Plc | 16.8 Million USD | 95.448% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | 66.358% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 99.744% |
| Lexaria Bioscience Corp. | 6.72 Million USD | 88.631% |
| UroGen Pharma Ltd. | 138.88 Million USD | 99.449% |
| Sutro Biopharma, Inc. | 243 Million USD | 99.685% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | 89.484% |
| Orgenesis Inc. | 45.75 Million USD | 98.328% |
| Entera Bio Ltd. | 8.86 Million USD | 91.366% |
| GH Research PLC | 41.22 Million USD | 98.144% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | 97.024% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | 99.079% |
| Xencor, Inc. | 306.97 Million USD | 99.751% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | 84.494% |
| Replimune Group, Inc. | 234.77 Million USD | 99.674% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | 96.266% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 99.601% |
| Lexaria Bioscience Corp. | 6.72 Million USD | 88.631% |
| Portage Biotech Inc. | 18.19 Million USD | 95.796% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | 89.462% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | 99.271% |
| OncoCyte Corporation | 25.63 Million USD | 97.016% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | 87.45% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | 93.323% |
| Purple Biotech Ltd. | -22.46 Million USD | 103.405% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | 95.358% |
| scPharmaceuticals Inc. | 65.17 Million USD | 98.826% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | 90.95% |
| HilleVax, Inc. | 133.34 Million USD | 99.426% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | 92.562% |
| Tharimmune, Inc. | 9.45 Million USD | 91.909% |
| Genprex, Inc. | 31.06 Million USD | 97.537% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 99.592% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | 97.562% |
| Virios Therapeutics, Inc. | 5.44 Million USD | 85.955% |
| OKYO Pharma Limited | 8243.57 USD | -9179.96% |
| Savara Inc. | 15.74 Million USD | 95.141% |
| Curis, Inc. | 58.35 Million USD | 98.689% |
| Daré Bioscience, Inc. | 33.6 Million USD | 97.724% |
| Carmell Therapeutics Corporation | 5.09 Million USD | 84.978% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | 89.747% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | 97.169% |
| BeiGene, Ltd. | 3.28 Billion USD | 99.977% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | 96.163% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 99.847% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | 99.502% |
| Erasca, Inc. | 141.52 Million USD | 99.459% |
| bluebird bio, Inc. | 240.23 Million USD | 99.682% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | 83.101% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 99.956% |
| DBV Technologies S.A. | 92.16 Million USD | 99.17% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | 83.101% |
| Moderna, Inc. | 6.39 Billion USD | 99.988% |
| Vincerx Pharma, Inc. | 42.6 Million USD | 98.205% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | 94.675% |
| Molecular Templates, Inc. | 63.09 Million USD | 98.787% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | 98.853% |
| Travere Therapeutics, Inc. | 472 Million USD | 99.838% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | 99.466% |
| Spruce Biosciences, Inc. | 62.08 Million USD | 98.768% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | 98.238% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 99.632% |
| MacroGenics, Inc. | 217.21 Million USD | 99.648% |
| RenovoRx, Inc. | 11.39 Million USD | 93.287% |
| Adicet Bio, Inc. | 152.03 Million USD | 99.497% |
| Prime Medicine, Inc. | 186.63 Million USD | 99.59% |
| Aditxt, Inc. | 25.95 Million USD | 97.052% |
| Adagene Inc. | 41.83 Million USD | 98.171% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | 89.535% |
| Quantum-Si incorporated | 111.65 Million USD | 99.315% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | 99.555% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | 94.752% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | 97.864% |
| SciSparc Ltd. | 9.01 Million USD | 91.51% |
| Vericel Corporation | 142.04 Million USD | 99.461% |
| Revelation Biosciences, Inc. | 8.65 Million USD | 91.163% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | 96.687% |
| Generation Bio Co. | 144.46 Million USD | 99.47% |
| Astria Therapeutics, Inc. | 83.03 Million USD | 99.079% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | 99.115% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 99.741% |
| Invivyd, Inc. | 205.75 Million USD | 99.628% |
| Relay Therapeutics, Inc. | 72.15 Million USD | 98.94% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | 91.843% |
| Spero Therapeutics, Inc. | 75.25 Million USD | 98.983% |
| Artelo Biosciences, Inc. | 10.28 Million USD | 92.563% |
| 2seventy bio, Inc. | 289.88 Million USD | 99.736% |
| ADMA Biologics, Inc. | 66.58 Million USD | 98.851% |
| Clene Inc. | 41.07 Million USD | 98.137% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | 94.027% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | 98.604% |
| GeoVax Labs, Inc. | 6.02 Million USD | 87.297% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 99.783% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | 97.917% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | 97.732% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | 99.262% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 97.653% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | 99.551% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 99.9% |
| Evaxion Biotech A/S | 22.27 Million USD | 96.565% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | 99.436% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 99.674% |
| Trevena, Inc. | 38.41 Million USD | 98.008% |
| Surrozen, Inc. | 18.55 Million USD | 95.876% |
| Tyra Biosciences, Inc. | 79.94 Million USD | 99.043% |
| Cingulate Inc. | 22.75 Million USD | 96.639% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 110.211% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 98.287% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | 90.709% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | 99.254% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 99.899% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | 98.768% |
| Clearmind Medicine Inc. | 8.74 Million USD | 91.248% |
| Kronos Bio, Inc. | 128.11 Million USD | 99.403% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | 99.09% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | 73.917% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 99.241% |
| Statera Biopharma, Inc. | 28.82 Million USD | 97.346% |
| ImmunityBio, Inc. | 362.87 Million USD | 99.789% |
| Korro Bio, Inc. | 84.53 Million USD | 99.095% |
| Kineta, Inc. | 21.15 Million USD | 96.384% |
| BioVie Inc. | 31.95 Million USD | 97.606% |
| Codexis, Inc. | 66.51 Million USD | 98.85% |
| Celularity Inc. | 215.05 Million USD | 99.644% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 99.662% |
| Celcuity Inc. | 66.23 Million USD | 98.845% |
| Virax Biolabs Group Limited | 6.54 Million USD | 88.315% |
| Cibus, Inc. | 320.3 Million USD | 99.761% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | 98.221% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 97.74% |
| IN8bio, Inc. | 30.33 Million USD | 97.478% |
| Kodiak Sciences Inc. | 277.32 Million USD | 99.724% |
| Annexon, Inc. | 143.72 Million USD | 99.468% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | 99.4% |
| Assembly Biosciences, Inc. | 22.9 Million USD | 96.661% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -19.531% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 99.902% |
| Eyenovia, Inc. | 25.4 Million USD | 96.989% |
| Puma Biotechnology, Inc. | 140.31 Million USD | 99.455% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | 86.246% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | 99.033% |
| Arcellx, Inc. | 200.19 Million USD | 99.618% |
| Cardiff Oncology, Inc. | 45.9 Million USD | 98.333% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 99.647% |
| Regulus Therapeutics Inc. | 9.95 Million USD | 92.317% |
| Moolec Science SA | 52.75 Million USD | 98.55% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | 98.749% |
| Geron Corporation | 70.44 Million USD | 98.914% |
| LAVA Therapeutics N.V. | 46.54 Million USD | 98.356% |
| Royalty Pharma plc | 862.4 Million USD | 99.911% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | 99.187% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | 91.799% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | 96.619% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 99.632% |
| Humacyte, Inc. | 23.49 Million USD | 96.744% |
| Structure Therapeutics Inc. | 102.77 Million USD | 99.256% |
| 89bio, Inc. | 151.2 Million USD | 99.494% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | 99.045% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | 94.739% |
| Genelux Corporation | 24.33 Million USD | 96.856% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | 97.745% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 99.557% |
| Notable Labs, Ltd. | 14.77 Million USD | 94.821% |
| Liquidia Corporation | 87.98 Million USD | 99.131% |
| Mustang Bio, Inc. | 48.5 Million USD | 98.423% |
| Immunovant, Inc. | 282.7 Million USD | 99.729% |
| Quantum-Si incorporated | 111.65 Million USD | 99.315% |
| Arbutus Biopharma Corporation | 22.54 Million USD | 96.607% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | 96.403% |
| Vera Therapeutics, Inc. | 102.01 Million USD | 99.25% |
| Acasti Pharma Inc. | 11.3 Million USD | 93.231% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | 96.662% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | 95.213% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | 98.356% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | 32.574% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | 95.184% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | 97.376% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | 98.151% |
| PepGen Inc. | 84.76 Million USD | 99.098% |
| Moleculin Biotech, Inc. | 29.63 Million USD | 97.418% |
| United Therapeutics Corporation | 885.1 Million USD | 99.914% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | 96.659% |
| Solid Biosciences Inc. | 104.31 Million USD | 99.267% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | 97.662% |
| Immuneering Corporation | 58.41 Million USD | 98.69% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | 84.971% |
| Silo Pharma, Inc. | 3.92 Million USD | 80.494% |
| Belite Bio, Inc | 31.66 Million USD | 97.584% |
| XOMA Corporation | 46.46 Million USD | 98.354% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | 98.868% |
| Bionomics Limited | 17.89 Billion USD | 99.996% |
| Apogee Therapeutics, Inc. | 93 Million USD | 99.177% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 102.144% |
| uniQure N.V. | 285.08 Million USD | 99.732% |
| Cassava Sciences, Inc. | 105.95 Million USD | 99.278% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | 89.535% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 99.606% |
| Forte Biosciences, Inc. | 32.47 Million USD | 97.644% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | 90.793% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | 97.398% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | 86.246% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | 94.616% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | 91.394% |
| Altimmune, Inc. | 30.55 Million USD | 97.496% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 99.821% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 102.144% |
| Compugen Ltd. | 43.97 Million USD | 98.26% |
| Peak Bio, Inc. | 1249.13 USD | -61142.625% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | 98.968% |
| Benitec Biopharma Inc. | 22.38 Million USD | 96.582% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 99.685% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | 97.32% |
| Zura Bio Limited | 62.63 Million USD | 98.779% |
| PolyPid Ltd. | 21.04 Million USD | 96.365% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | 95.3% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | 97.32% |
| Instil Bio, Inc. | 85.78 Million USD | 99.108% |
| argenx SE | 1.53 Billion USD | 99.95% |
| Immunome, Inc. | 122.82 Million USD | 99.377% |
| Compass Therapeutics, Inc. | 48.47 Million USD | 98.422% |
| Verona Pharma plc | 67.15 Million USD | 98.861% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | 97.045% |
| Shattuck Labs, Inc. | 93.61 Million USD | 99.183% |
| CervoMed Inc. | 14.95 Million USD | 94.886% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | 98.918% |
| Plus Therapeutics, Inc. | 8.54 Million USD | 91.046% |
| Dianthus Therapeutics, Inc. | 51 Million USD | 98.5% |
| Moolec Science SA | 52.75 Million USD | 98.55% |
| Enveric Biosciences, Inc. | 16.44 Million USD | 95.349% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | 99.423% |
| AnaptysBio, Inc. | 181.56 Million USD | 99.579% |
| Design Therapeutics, Inc. | 78.19 Million USD | 99.022% |
| Leap Therapeutics, Inc. | 87.04 Million USD | 99.121% |
| NeurAxis, Inc. | 8.82 Million USD | 91.328% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | 93.921% |
| Lumos Pharma, Inc. | 38.66 Million USD | 98.021% |
| Achilles Therapeutics plc | 75.25 Million USD | 98.983% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | 97.045% |
| 180 Life Sciences Corp. | 13.47 Million USD | 94.324% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | 97.113% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | 73.917% |
| Nutriband Inc. | 5.73 Million USD | 86.659% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | 99.309% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | 98.625% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | 98.496% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | 98.843% |
| MoonLake Immunotherapeutics | 54.12 Million USD | 98.587% |
| Palisade Bio, Inc. | 13.32 Million USD | 94.257% |
| Tourmaline Bio, Inc. | 45.4 Million USD | 98.315% |
| Beam Therapeutics Inc. | 554.19 Million USD | 99.862% |
| Neurogene Inc. | 55.58 Million USD | 98.624% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 99.692% |
| AEON Biopharma, Inc. | 48.42 Million USD | 98.42% |
| Sesen Bio, Inc. | 78.38 Million USD | 99.024% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | 99.084% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | 93.922% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 99.83% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | 99.13% |
| Athira Pharma, Inc. | 125.46 Million USD | 99.39% |
| Vaccinex, Inc. | 23.45 Million USD | 96.738% |
| HCW Biologics Inc. | 21.02 Million USD | 96.362% |
| XOMA Corporation | 46.46 Million USD | 98.354% |
| Nektar Therapeutics | 190.9 Million USD | 99.599% |
| Arvinas, Inc. | 480 Million USD | 99.841% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | 66.358% |
| Merus N.V. | 200.49 Million USD | 99.618% |
| Omega Therapeutics, Inc. | 103.35 Million USD | 99.26% |
| Quince Therapeutics, Inc. | 34.62 Million USD | 97.79% |
| Rezolute, Inc. | 70.38 Million USD | 98.913% |
| Clene Inc. | 41.07 Million USD | 98.137% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | 95.329% |
| BeyondSpring Inc. | 24.86 Million USD | 96.923% |
| Synlogic, Inc. | 58.53 Million USD | 98.693% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | 95.724% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | 82.97% |
| Peak Bio, Inc. | 1249.13 USD | -61142.625% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | 98.734% |
| Krystal Biotech, Inc. | 160.42 Million USD | 99.523% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 99.717% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 99.78% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | 64.53% |
| MannKind Corporation | 125.59 Million USD | 99.391% |
| Ikena Oncology, Inc. | 84.57 Million USD | 99.095% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | 92.07% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | 99.146% |
| Gossamer Bio, Inc. | 183.75 Million USD | 99.584% |
| CohBar, Inc. | 12.38 Million USD | 93.825% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | 98.492% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 97.226% |
| Legend Biotech Corporation | 583.14 Million USD | 99.869% |
| Mural Oncology plc | 192.07 Million USD | 99.602% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 98.861% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | 95.262% |
| Disc Medicine, Inc. | 91.12 Million USD | 99.16% |
| Champions Oncology, Inc. | 28.11 Million USD | 97.279% |
| REGENXBIO Inc. | 321.15 Million USD | 99.762% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | 85.731% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 98.628% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | 98.036% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | 99.331% |
| Vaxart, Inc. | 90.72 Million USD | 99.157% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | 91.021% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | 98.212% |
| Cellectis S.A. | 97.32 Million USD | 99.214% |
| Longeveron Inc. | 21.25 Million USD | 96.4% |
| Repare Therapeutics Inc. | 167.35 Million USD | 99.543% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 99.944% |
| Inozyme Pharma, Inc. | 75.64 Million USD | 98.989% |
| Revolution Medicines, Inc. | 498.76 Million USD | 99.847% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | 88.5% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | 98.26% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | 98.974% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | 98.901% |
| Anixa Biosciences, Inc. | 11.06 Million USD | 93.083% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.984% |
| Denali Therapeutics Inc. | 527.23 Million USD | 99.855% |
| Revelation Biosciences, Inc. | 8.65 Million USD | 91.163% |
| Veru Inc. | 101.34 Million USD | 99.245% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | 96.732% |
| Cingulate Inc. | 22.75 Million USD | 96.639% |
| Passage Bio, Inc. | 108.38 Million USD | 99.294% |
| Context Therapeutics Inc. | 25.07 Million USD | 96.949% |
| Exicure, Inc. | 14.07 Million USD | 94.565% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 99.629% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | 98.233% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | 91.664% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 99.697% |
| Nuvalent, Inc. | 149.49 Million USD | 99.488% |
| ABVC BioPharma, Inc. | 8.06 Million USD | 90.517% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | 99.262% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | 96.433% |
| OmniAb, Inc. | 83.89 Million USD | 99.088% |
| Anew Medical, Inc. | 1.3 Million USD | 41.192% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | 97.665% |
| Lipocine Inc. | 15.08 Million USD | 94.927% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | 98.883% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | 98.995% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 98.102% |
| G1 Therapeutics, Inc. | 114.84 Million USD | 99.334% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | 96.582% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 99.885% |
| Ocugen, Inc. | 71.56 Million USD | 98.931% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | 99.185% |
| Q32 Bio Inc. | 92.68 Million USD | 99.175% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | 96.387% |
| Alumis Inc. Common Stock | 158.17 Million USD | 99.516% |
| Equillium, Inc. | 50.6 Million USD | 98.488% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | 98.774% |
| Coya Therapeutics, Inc. | 13.9 Million USD | 94.499% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | 95.945% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 98.371% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 99.295% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | 93.827% |
| Dominari Holdings Inc. | 23.83 Million USD | 96.79% |
| Edesa Biotech, Inc. | 9.22 Million USD | 91.705% |
| vTv Therapeutics Inc. | 11.9 Million USD | 93.575% |
| Bio-Techne Corporation | 563.03 Million USD | 99.864% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 99.813% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 99.715% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | 99.422% |
| Candel Therapeutics, Inc. | 14.41 Million USD | 94.692% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | 99.533% |
| Nkarta, Inc. | 131.65 Million USD | 99.419% |
| BioCardia, Inc. | 12.12 Million USD | 93.689% |
| Iterum Therapeutics plc | 47.46 Million USD | 98.388% |